Literature DB >> 11897288

Fatal allergic vasculitis associated with celecoxib.

F Schneider, F Meziani, C Chartier, M Alt, A Jaeger.   

Abstract

We report on the occurrence of a rare and as yet unforseeable adverse reaction to treatment with celecoxib, a cyclooxygenase-2 (COX-2) selective, non-steroidal, anti-inflammatory drug. A previously healthy adult suffered fatal acute multiple organ failure presumably after diffuse allergic vasculitis with diffuse necrotic purpura. Although no conclusive proof is available, such a reaction could have been triggered by at least one of two mechanisms: an allergic reaction linked to the chemical structure of celecoxib; or an interaction of the drug with synthesis of endothelial eiconasoids leading to an imbalance between vasoactive end products, resulting in widespread rise to local thrombosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897288     DOI: 10.1016/S0140-6736(02)07922-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Adverse reactions induced by NSAIDs and antibacterials: analysis of spontaneous reports from the Sicilian regional database.

Authors:  Giovanni Polimeni; Francesco Salvo; Paola Cutroneo; Ilaria Morreale; Achille Patrizio Caputi
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  2-(2-Arylphenyl)benzoxazole As a Novel Anti-Inflammatory Scaffold: Synthesis and Biological Evaluation.

Authors:  Kapileswar Seth; Sanjeev K Garg; Raj Kumar; Priyank Purohit; Vachan S Meena; Rohit Goyal; Uttam C Banerjee; Asit K Chakraborti
Journal:  ACS Med Chem Lett       Date:  2014-02-17       Impact factor: 4.345

Review 3.  [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Authors:  Eva S Schernhammer; Christian Dittrich
Journal:  Wien Med Wochenschr       Date:  2003

4.  Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.

Authors:  Jochen Tuettenberg; Rainer Grobholz; Tobias Korn; Frederik Wenz; Ralf Erber; Peter Vajkoczy
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

5.  Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors:  Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 6.  COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

Authors:  Samir Malhotra; N Shafiq; P Pandhi
Journal:  MedGenMed       Date:  2004-03-23

7.  [NSAIDs and COX-2-inhibitors: current status].

Authors:  C Kneitz; H P Tony; K Krüger
Journal:  Internist (Berl)       Date:  2006-05       Impact factor: 0.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.